Abstract Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler
syndrome, is a genetic vascular disorder affecting 1 in 5000–8000 individuals worldwide …

Arteriovenous malformations are a vascular anomaly typically present at birth, characterized
by an abnormal connection between an artery and a vein (bypassing the capillaries). These …

Background: Activin receptor-like kinase 1 (ALK1) is an endothelial transmembrane serine
threonine kinase receptor for BMP family ligands that plays a critical role in cardiovascular …

Major traumatic tissue defects are common clinical problems often complicated by infection
and local vascular dysfunction, processes which hinder the healing process. Although local …

Hereditary hemorrhagic telangiectasia (HHT) management is evolving because of the
emergence and development of antiangiogenic therapies to eliminate bleeding …

The endothelial cells that compose the vascular system in the body display a wide range of
mechanotransductive behaviors and responses to biomechanical stimuli, which act in …

Background Bevacizumab—a humanized monoclonal antibody—has been widely used to
treat patients with hereditary hemorrhagic telangiectasia (HHT), but no randomized trial has …

Hereditary haemorrhagic telangiectasia (HHT) is characterised by arteriovenous
malformations (AVMs). These vascular abnormalities form when arteries and veins directly …

Endoglin (ENG) is expressed on the surface of endothelial cells (ECs) where it efficiently
binds circulating BMP9 and BMP10 ligands to initiate activin A receptor like type 1 (ALK1) …

Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by vessel
dilatation, such as telangiectasia in skin and mucosa and arteriovenous malformations …